Abstract
The activity of adenylate cyclase in the hepatocyte plasma membranes, content of cAMP, and cAMP/cGMP ratio in the liver and blood plasma are decreased in patients with chronic liver diseases (fatty dystrophy, chronic hepatitis, and cirrhosis). This decrease depends on the disease severity and is most pronounced in cirrhosis. The sensitivity of liver adenylate cyclase to insulin and glucagon is changed. It is concluded that disorders in the adenylate cyclase system are an important molecular mechanism in the pathogenesis of chronic liver diseases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
